Tweet
Hi, we are looking for gut microbiome by targeting V3V4 and ITS2 regions through Illumina-MiSeq platform and would like to analyse the data using QIIME and other bioinformatics pipelines. Our data consists of 500,000 to 800,000 reads per sample. The comparative analysis would range from 40 to 100 samples (maximum). In this regard, it would be grateful, if someone tell us the suitable configuration (RAM, hard disk space, processor, number of cores, number of threads etc) for buying the workstation.
-
-
Are you working within a certain budget or is that not a consideration?
You will find several workstation threads here (and elsewhere on the net) and most of those recommendations should work well for you. In general try to maximize the RAM, get a solid state drive for OS, go with the second or third fastest processor(s) you can afford (not much gain in getting the top of the line/most expensive CPU) and finally as much spinning disk as you can fit in your remaining budget. -
Minimum configuration required for analyzing MiSeq data (by V3V4, ITS2) on QIIME
Hi GenoMax, thankyou for your reply. I would like to know the minimum configuration required for analyzing the data which I have posted earlier, so that I can plan for a workstation within our budget accordingly. [Whether 32 GB RAM, Intel® Core™ i7-6700 CPU @ 3.40GHz × 8 processor (http://ark.intel.com/products/88196/...up-to-4_00-GHz) , 1 TB hard disk space are sufficient and optimal for such analysis?, if higher configuration is required, what will you suggest?].Comment
-
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM -
Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.07-01-2026, 11:43 AM
Comment